TEST:

PANAMutyper™ R EGFR

Good detection sensitivity (~80%) was observed despite the limited volume (1 mL) and long-term storage (12-50 months) of plasma used and is expected to increase with high cfDNA inputs. Thus, the ULV1 panel is a fast and cost-effective method for early diagnosis, treatment selection, and clinical follow-up of patients with NSCLC.

"Panagene said on Monday it signed a contract with Yuhan Corp. to jointly develop the original companion diagnostic (CDx), called PANAMutyper R EGFR, for Yuhan’s lung cancer drug Leclaza (lazertinib)....A Yuhan official said that pursuing clinical trials and licensing of PANAMutyper R EGFR as the original companion diagnosis of Leclaza together with Panagene, a leader in domestic companion diagnosis, will be a new milestone in the development of CDx in Korea."